## **POSTER PRESENTATION**



**Open Access** 

# Transmission dynamics of *vivax* malaria in Korea: effectiveness of anti-malarial chemoprophylaxis

Akira Endo<sup>\*</sup>, Hiroshi Nishiura

*From* Challanges in malaria research: Core science and innovation Oxford, UK. 22-24 September 2014

### Background

*Vivax* malaria with two distinct (short- and long-term) incubation periods has been prevalent in the Republic of Korea since its re-emergence in 1993. Chemoprophylaxis has been conducted among military personnel since 1997. We estimated the time-dependent reproduction number, thereby assessing the protective effect of chemoprophylaxis.

### Materials and methods

A mathematical model has been formulated using a renewal equation, estimating the yearly reproduction number (Ry) from 1993 to 2012 by maximum likelihood estimation method. We also computed Akaike Information Criterion (AIC) to test if there was a detectable change point in the trend in relation to chemoprophylaxis.

### Results

Three-year average of Ry showed gradual decline through 1993-2012 with a temporary increase from 2003 to 2005, having been under the threshold 1 since 1998. AIC has suggested that the chemoprophylaxis has cut down Ry by 34% from what it would be without chemoprophylaxis.

### Conclusions

The epidemic of *vivax* malaria in Korea has been brought under control due mainly to mass-chemoprophylaxis.

Published: 22 September 2014

doi:10.1186/1475-2875-13-S1-P29 Cite this article as: Endo and Nishiura: Transmission dynamics of *vivax* malaria in Korea: effectiveness of anti-malarial chemoprophylaxis. *Malaria Journal* 2014 13(Suppl 1):P29.

The University of Tokyo, Tokyo, Japan



- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

) Bio Med Central

Submit your manuscript at www.biomedcentral.com/submit



© 2014 Endo and Nishiura; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.